A novel PAA derivative with enhanced drug efficacy in pancreatic cancer cell lines

Ali Alsuraifi, Paul Kong Thoo Lin, Anthony Curtis, Dimitrios A. Lamprou, Clare Hoskins

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity.
The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL−1 and 2.4 mg mL−1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50% cell population at concentrations as low as 3 µg mL−1
.
Original languageEnglish
Article number91
Number of pages13
JournalPharmaceuticals
Volume11
Issue number4
DOIs
Publication statusPublished - 8 Oct 2018

Fingerprint

Pancreatic Neoplasms
Cell Line
Allylamine
Pharmaceutical Preparations
Naphthalimides
Drug Carriers
Multiple Drug Resistance
Nanoparticles
Neoplasms
Polymers
Therapeutics
Population

Keywords

  • nanomedicine
  • nanopharmaceutics
  • drug solubilisation
  • pancreatic cancer
  • bisnaphthalimide

Cite this

Alsuraifi, Ali ; Kong Thoo Lin, Paul ; Curtis, Anthony ; Lamprou, Dimitrios A. ; Hoskins, Clare. / A novel PAA derivative with enhanced drug efficacy in pancreatic cancer cell lines. In: Pharmaceuticals. 2018 ; Vol. 11, No. 4.
@article{c1f42cd4b2c24e1aa46935520b929ce7,
title = "A novel PAA derivative with enhanced drug efficacy in pancreatic cancer cell lines",
abstract = "Nanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity.The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL−1 and 2.4 mg mL−1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50{\%} cell population at concentrations as low as 3 µg mL−1.",
keywords = "nanomedicine, nanopharmaceutics, drug solubilisation, pancreatic cancer, bisnaphthalimide",
author = "Ali Alsuraifi and {Kong Thoo Lin}, Paul and Anthony Curtis and Lamprou, {Dimitrios A.} and Clare Hoskins",
year = "2018",
month = "10",
day = "8",
doi = "10.3390/ph11040091",
language = "English",
volume = "11",
journal = "Pharmaceuticals",
issn = "1424-8247",
number = "4",

}

A novel PAA derivative with enhanced drug efficacy in pancreatic cancer cell lines. / Alsuraifi, Ali; Kong Thoo Lin, Paul; Curtis, Anthony; Lamprou, Dimitrios A.; Hoskins, Clare.

In: Pharmaceuticals, Vol. 11, No. 4, 91, 08.10.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel PAA derivative with enhanced drug efficacy in pancreatic cancer cell lines

AU - Alsuraifi, Ali

AU - Kong Thoo Lin, Paul

AU - Curtis, Anthony

AU - Lamprou, Dimitrios A.

AU - Hoskins, Clare

PY - 2018/10/8

Y1 - 2018/10/8

N2 - Nanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity.The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL−1 and 2.4 mg mL−1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50% cell population at concentrations as low as 3 µg mL−1.

AB - Nanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity.The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL−1 and 2.4 mg mL−1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50% cell population at concentrations as low as 3 µg mL−1.

KW - nanomedicine

KW - nanopharmaceutics

KW - drug solubilisation

KW - pancreatic cancer

KW - bisnaphthalimide

U2 - 10.3390/ph11040091

DO - 10.3390/ph11040091

M3 - Article

VL - 11

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 4

M1 - 91

ER -